Adverse health outcomes for prostate cancer patients treated with radiotherapy combined with androgen-deprivation therapy: A population-based, controlled study, from Norway
DOI:
https://doi.org/10.2340/1651-226X.2025.42825Keywords:
Prostate cancer, Radiotherapy, Androgen deprivation therapy, EPIC-26 domain summary scores, Quality of life, Late effectsAbstract
Background and purpose : The aim of this controlled cross-sectional, and population-based study was to evaluate adverse health outcomes (AHOs) 3 years after curative radiotherapy (RT) + androgen deprivation therapy (ADT). We also assessed Global Health/Quality of Life (QoL).
Patients/material and methods: The Cancer Registry of Norway (CRN) provided data on prostate cancer (PCa) patients diagnosed in 2017–2019. All had been treated with RT+ ADT. All had completed EPIC-26 and EORTC QLQ-C30 about 3 years after RT start (n = 663). ADT duration was stratified: Short (< 9 months), intermediate (9–18 months) and long ADT (18–24 months). A group of controls were established from the general population (n = 1,817). Outcome measures were the urinary irritative/obstructive domain summary score (DSS), the bowel and sexual DSSs (EPIC-26) and QoL (EORTC QLQ-C30).
Results: Compared to controls, patients had clinically important lower bowel, and sexual mean scores. Urinary irritative/obstructive DSS levels were similar. Overall, 43% (PCa patients) and 20% (controls) reported major sexual problems. In patients aged < 75 years, longer than short ADT duration significantly decreased sexual DSS. QoL was relatively unaffected. Low response rates, selection bias and a lack of pre-treatment data represent the studys´ limitations.
Conclusion and Interpretation: Three years post-RT+ADT, PCa patients describe clinically important lower EPIC-26 bowel and sexual DSS compared to controls. Sexual domain levels decreased with increasing ADT duration, particularly in patients < 75 years. Our observations indicate worse AHOs than previously reported and should be considered during pre-treatment counselling of PCa patients.
Downloads
References
Cornford P, Van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86(2):148–63.
https://doi.org/10.1016/j.eururo.2024.03.027 DOI: https://doi.org/10.1016/j.eururo.2024.03.027
Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Holding P, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid. 2023;2(4). DOI: https://doi.org/10.1056/EVIDx2300122
Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, et al. Patient-reported outcomes Through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323(2):149–63.
https://doi.org/10.1001/jama.2019.20675 DOI: https://doi.org/10.1001/jama.2019.20675
Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368(5):436–45.
https://doi.org/10.1056/NEJMoa1209978 DOI: https://doi.org/10.1056/NEJMoa1209978
Wallis CJD, Glaser A, Hu JC, Huland H, Lawrentschuk N, Moon D, et al. Survival and complications following surgery and radiation for localized prostate cancer: an international collaborative review. Eur Urol. 2018;73(1):11–20.
https://doi.org/10.1016/j.eururo.2017.05.055 DOI: https://doi.org/10.1016/j.eururo.2017.05.055
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61.
https://doi.org/10.1056/NEJMoa074311 DOI: https://doi.org/10.1056/NEJMoa074311
Ávila M, Patel L, López S, Cortés-Sanabria L, Garin O, Pont À, et al. Patient-reported outcomes after treatment for clinically localized prostate cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2018;66:23–44.
https://doi.org/10.1016/j.ctrv.2018.03.005 DOI: https://doi.org/10.1016/j.ctrv.2018.03.005
Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, et al. External beam radiation therapy or brachytherapy with or without short-course neoadjuvant androgen deprivation therapy: results of a multicenter, prospective study of quality of life. Int J Radiat Oncol Biol Phys. 2017;98(2):304–17.
https://doi.org/10.1016/j.ijrobp.2017.02.019 DOI: https://doi.org/10.1016/j.ijrobp.2017.02.019
Corsini C, Bergengren O, Carlsson S, Garmo H, Hjelm-Eriksson M, Fransson P, et al. Patient-reported side effects 1 year after radical prostatectomy or radiotherapy for prostate cancer: a register-based nationwide study. Eur Urol Oncol. 2024;7(3):605–613.
https://doi.org/10.1016/j.euo.2023.12.007 DOI: https://doi.org/10.1016/j.euo.2023.12.007
Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA. 2017;317(11):1126–40.
https://doi.org/10.1001/jama.2017.1704 DOI: https://doi.org/10.1001/jama.2017.1704
Smith DP, King MT, Egger S, Berry MP, Stricker PD, Cozzi P, et al. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. BMJ. 2009;339:b4817.
https://doi.org/10.1136/bmj.b4817 DOI: https://doi.org/10.1136/bmj.b4817
Caumont F, Conti G, Hurwitz LM, Kuo C, Levie KE, Badiozamani K, et al. A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy. Urol Oncol. 2020;38(10):794.e1–9.
https://doi.org/10.1016/j.urolonc.2020.02.007 DOI: https://doi.org/10.1016/j.urolonc.2020.02.007
Punnen S, Cowan JE, Chan JM, Carroll PR, Cooperberg MR. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015;68(4):600–8.
https://doi.org/10.1016/j.eururo.2014.08.074 DOI: https://doi.org/10.1016/j.eururo.2014.08.074
Taylor KL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30(22):2768–75.
https://doi.org/10.1200/JCO.2011.41.2767 DOI: https://doi.org/10.1200/JCO.2011.41.2767
Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, et al. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. 2016;117(6b):E36–45.
https://doi.org/10.1111/bju.13179 DOI: https://doi.org/10.1111/bju.13179
Fosså SD, Dahl AA, Johannesen TB, Gjelsvik YM, Storås AH, Myklebust T. Late adverse health outcomes and quality of life after curative radiotherapy + long-term ADT in prostate cancer survivors: comparison with men from the general population. Clin Transl Radiat Oncol. 2022;37:78–84.
https://doi.org/10.1016/j.ctro.2022.08.003 DOI: https://doi.org/10.1016/j.ctro.2022.08.003
Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, et al. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Lancet Oncol. 2012;13(12):1260–70.
https://doi.org/10.1016/S1470-2045(12)70423-0 DOI: https://doi.org/10.1016/S1470-2045(12)70423-0
Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360(24):2516–27.
https://doi.org/10.1056/NEJMoa0810095 DOI: https://doi.org/10.1056/NEJMoa0810095
Gjelsvik YM, Myklebust TÅ, Fosså SD, Haug ES, Kvåle R,. Ursin G, et al. A nationwide, longitudinal collection of patient-reported outcomes from prostate cancer patients and controls. Qual Life Res. 2025;33.
https://doi.org/10.1007/s11136-025-04017-7 DOI: https://doi.org/10.1007/s11136-025-04017-7
Scoring Instructions for the Expanded Prostate cancer Index Composite Short Form (EPIC-26) Available from: https://medicine.umich.edu/sites/default/files/content/downloads/Scoring%20Instructions%20for%20the%20EPIC%2026.pdf
Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E, et al. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. Lancet Oncol. 2019;20(3):436–47.
https://doi.org/10.1016/S1470-2045(18)30780-0 DOI: https://doi.org/10.1016/S1470-2045(18)30780-0
Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, Wei JT. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015;85(1):101–5.
https://doi.org/10.1016/j.urology.2014.08.044 DOI: https://doi.org/10.1016/j.urology.2014.08.044
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.
https://doi.org/10.1093/jnci/85.5.365 DOI: https://doi.org/10.1093/jnci/85.5.365
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139–44.
https://doi.org/10.1200/JCO.1998.16.1.139 DOI: https://doi.org/10.1200/JCO.1998.16.1.139
Akbal C, Tinay I, Simşek F, Turkeri LN. Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment. Int Urol Nephrol. 2008;40(2):355–63.
https://doi.org/10.1007/s11255-007-9247-1 DOI: https://doi.org/10.1007/s11255-007-9247-1
Pinkawa M, Gagel B, Piroth MD, Fischedick K, Asadpour B, Kehl M, et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol. 2009;55(1):227–34.
https://doi.org/10.1016/j.eururo.2008.03.026 DOI: https://doi.org/10.1016/j.eururo.2008.03.026
Incrocci L, Slob AK. Incidence, etiology, and therapy for erectile dysfunction after external beam radiotherapy for prostate cancer. Urology. 2002;60(1):1–7.
https://doi.org/10.1016/S0090-4295(02)01659-X DOI: https://doi.org/10.1016/S0090-4295(02)01659-X
Nossiter J, Sujenthiran A, Cowling TE, Parry MG, Charman SC, Cathcart P, et al. Patient-reported functional outcomes after hypofractionated or conventionally fractionated radiation for prostate cancer: a National Cohort Study in England. J Clin Oncol. 2020;38(7):744–752.
https://doi.org/10.1200/JCO.19.01538 DOI: https://doi.org/10.1200/JCO.19.01538
Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20(2):557–66.
https://doi.org/10.1200/JCO.2002.20.2.557 DOI: https://doi.org/10.1200/JCO.2002.20.2.557
Donnelly DW, Donnelly C, Kearney T, Weller D, Sharp L, Downing A, et al. Urinary, bowel and sexual health in older men from Northern Ireland. BJU Int. 2018;122(5):845–57.
https://doi.org/10.1111/bju.14182 DOI: https://doi.org/10.1111/bju.14182
Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009;27(24):3916–22.
https://doi.org/10.1200/JCO.2008.18.6486 DOI: https://doi.org/10.1200/JCO.2008.18.6486
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Mona Nilsson, Anne Holck Storaas, Tom Børge Johannesen, Ylva Maria Gjelsvik, Kirsti Aas, Sophie Dorthea Fosså, Tor Åge Myklebust
This work is licensed under a Creative Commons Attribution 4.0 International License.
